

Remarks

Reconsideration of this Application is respectfully requested.

Upon entry of the foregoing amendment, claims 41-145 are pending in the application, with claims 41 and 89 being the independent claims. Applicants have cancelled claims 1-40 without prejudice to or disclaimer of the subject matter therein. New claims 41-42, 51-53, and 74-88 read on the elected peptide. These changes are believed to introduce no new matter, and their entry is respectfully requested.

The specification has also been amended to perfect the claim for benefit of earlier applications. As this application was filed before November 29, 2000, the amendment of the claim for benefit is timely. 37 C.F.R. § 1.78 (a)(2)(ii)(C). MPEP § 201.11(E). Support for the incorporation by reference of the priority applications may be found in the original specification in the paragraph beginning at page 1, line 9.

Support for newly added claims 41-145 can be found throughout the specification. For the Examiner's convenience, **Table 1** (attached) sets out examples of locations where support for the new claims can be found in the present application and the priority applications.

Applicants have organized the independent claims to include peptides having the same priority dates to aid in examination. Thus, Applicants request examination of a reasonable number of peptides, notwithstanding the fact that they are recited in several independent claims. Applicants note that, to the best of Applicants' knowledge, the peptides recited in claims 41-50 were first disclosed in Appl. No. 09/098,584, filed June

17, 1998, and the peptides recited in claims 89-101 were first disclosed in Appl. No. 09/017,735, filed February 3, 1998. The applications listed above were originally incorporated by reference into the present application.

The specification has been amended in the paragraph beginning at page 12, line 29 to recite that CTL-inducing peptides of the invention can be less than about 15 residues in length. Support for this amendment can be found in priority Appl. No. 09/098,584 at page 5, lines 2-3 and in priority Appl. No. 09/017,735 at page 3, lines 23-25. These applications, as noted above, were originally incorporated by reference into the present application.

The specification has been amended to insert the Substitute Sequence Listing, submitted herewith, which has been changed to reflect the current priority claim. In accordance with 37 C.F.R. § 1.821(f), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith in the above-captioned application are the same. In accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

These changes are believed to introduce no new matter, and their entry is respectfully requested.

It is believed that the application is now in condition for examination. Early notice to this effect is respectfully requested.

Conclusion

Consideration of this Amendment is respectfully requested. Applicants respectfully submit that the application is in proper condition for allowance.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C..

Helene Carlson

Helene C. Carlson
Agent for Applicants
Registration No. 47,473

Date: 2/6/04
1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
222905_1.DOC



Table 1- Example of Support for Claims

<u>Claim Language</u>	<u>This Application</u>	<u>09/017,735</u>	<u>09/098,584</u>
T helper peptide	p. 50, line 17 through p.51, line 22	p.15, lines 6-22	p.16, lines 16-20
Spacer or linker	p.50, lines 22-30	p.15, lines 8-16	p. 16, lines 7-17
Carrier	p. 42, lines 28-30	p. 21, lines 6-7	p. 21, lines 23-24
Lipid	p. 51, line 25 through p. 52, line15	p. 16, lines 3-11	p. 16, lines 22-30
Fusion protein	p. 38, lines 12-18	p. 17, lines 3-4	p. 17, lines 29-30
Liposome	p. 56, line 1-17	p. 19, line 26 through p. 20, line 11	p. 20, lines 14-30
Homopolymer/ heteropolymer	p. 42, lines 28-30	p. 21, lines 6-7	p. 21, lines 23-24
Less than about 15 residues in length	p. 12, lines 32-34, as amended herewith	p. 3, lines 23-25	p. 5, lines 2-3
8, 9, 10, or 11 amino acids in length	p. 12, lines 32-34	p. 3, lines 23-25	p. 5, lines 2-3